Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content

Table 4 Summary of components to consider when evaluating the quality of evidence from research

From: Evidence-based medicine: Classifying the evidence from clinical trials – the need to consider other dimensions

Study design

Randomized

 

Allocation concealment

 

Blinding (if possible)a

 

Clinically important and objective primary outcome

 

Beta-errorb

 

Multi-center

Study conduct

Intention-to-treat analysis

 

Follow-up or attrition rate

 

Completion to planned numbers

Study findings

Biological plausibility

 

Strength of estimate of effect

 

Precision of estimate of effect

 

Observed event rate

Study applicability

Consistency across similar studies

 

Reproducibility

 

Generalizability

  1. aBlinding may not be possible in device or protocol/process trials. bAdequately powered, appropriate estimate of control event rate and relative or absolute reduction in clinically important primary outcome.
Back to article page

Critical Care

ISSN: 1364-8535